Synthetic LXR ligand inhibits the development of atherosclerosis in mice - Wikidata - wikimedia - TriplyDB

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

http://www.wikidata.org/entity/Q24530617

about

NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol Liver x receptors in atherosclerosis and inflammation PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1 MicroRNAs in lipid metabolism Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis Suppression of 2,3-oxidosqualene cyclase by high fat diet contributes to liver X receptor-alpha-mediated improvement of hepatic lipid profile LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia Linking lipids, Alzheimer's and LXRs?The clearance of dying cells: table for two Orphan nuclear receptors and the regulation of nutrient metabolism: understanding obesity From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch Crystal structure of the heterodimeric complex of LXR and RXR ligand-binding domains in a fully agonistic conformation Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases Liver X receptors at the intersection of lipid metabolism and atherogenesis Minireview: nuclear receptor coregulators of the p160 family: insights into inflammation and metabolism Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors Therapeutic potential of argan oil: a review Immune cell screening of a nanoparticle library improves atherosclerosis therapy Hyperlipidemia and atherosclerotic lesion development in Ldlr-deficient mice on a long-term high-fat diet An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2 Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.Liver X Receptors Link Lipid Metabolism and Inflammation.Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.Phenotypic polarization of macrophages in atherosclerosis Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice Nuclear receptors as drug targets for metabolic disease.LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse Lipid metabolism emerges as a promising target for malignant glioma therapy.Liver X receptor gene polymorphisms in tuberculosis: effect on susceptibility.

P2860

Q24300768-C1C283C6-8F74-4B70-ABB6-0A56FB14F4B0 Q24337296-8E78CE9C-841B-4FBA-8BB9-6D1396EFC3A2 Q24337975-2E94C31B-C55D-4864-A86E-4CF471316CE0 Q24608256-49FDBFB5-FAD3-42CB-BCBB-F8BBAB6304C2 Q24633440-B344313A-A3E0-45BF-A2CB-3D25BF48E499 Q24633633-94C51069-5CF0-42BD-8A9D-9E85782FC402 Q24634165-AB4A00F0-4DE0-4129-9447-FE0C9069F055 Q24647173-9C5D4266-F19C-4F7A-99E5-AEC34AB0A663 Q24656186-DA66B472-196F-4BAC-9791-A6B9E94AB916 Q24657127-7F9140BA-F4B3-4A37-BA21-46F135BCA72A Q25255165-EFB97F09-DDFB-461D-AD34-F524FFD35D54 Q26753825-0AC6C4E9-7BC8-404E-AC37-42DE9BC4FAD5 Q26823819-EDB30A36-B037-45F6-A979-D1446A28E074 Q26997647-86BDAD51-9278-4D18-A2A5-D21B59C4B139 Q27641169-F02E7DE4-EB2D-4A5B-9AC5-C3FDAFF3CF4D Q27642012-E3800B5F-FFFF-4AA1-BD0B-62C4557ECF78 Q28071254-6926F4B0-3D33-478F-9742-3E1E7DD755C0 Q28082452-5CCF7584-6FBE-420E-B618-F5BE79BB20AC Q28084780-65CFCCEE-EB99-4D4A-AF7E-588A6DAA4F47 Q28236615-98853154-1F66-4FB1-A460-B478B29D0404 Q28297797-5F85EED0-8B46-4E2C-8B6D-8C9D61C68F22 Q28393434-8E9191D3-3E46-4217-92A1-8BBFD2EDDDF8 Q28482520-509B8FF4-C9C6-4A2D-9D04-076611ABA69F Q28504786-A6C01DFE-8996-4C84-B677-C30D26E2F02E Q28513193-FF500B8F-4B68-4ABB-BC0A-558A34EE92BF Q28513582-7A40097A-452A-4957-90C5-99FDCD95116E Q28569109-83BC77FA-3D70-492D-B54D-77B8368A0318 Q28569337-9C17A0B9-984C-4627-8079-24D07561D82B Q28588482-CB7F4536-32BE-422D-80F4-DE4FCF93691E Q28588828-B8B0EC0B-ED7F-42BE-8E25-C72BCEF51BBF Q28589168-20F7764E-EB60-41B3-9FE4-0CCD54C389BD Q30252316-484BD28A-1667-4AFE-BCFA-A803E09B9BCB Q30371540-F292C18D-CFE0-40F0-B5FF-486E7F45B042 Q30412717-9BF45BBB-6383-4DBB-B7FD-2174D0F38D59 Q30418832-B58FBF01-25A5-479C-ADCF-71A6125F1358 Q30426995-F57F90A8-69C2-4F97-8BC4-BB2563A0C990 Q30430126-29E3C0B7-A999-49BC-A850-997B53C40251 Q30491802-B061B678-AF8B-4518-93CD-18959626BAE1 Q30684049-2F567FA0-6BF9-42E1-B82E-B03212F194C2 Q33553493-3D2194AE-4CB9-49E1-BE32-751EFEC19B8F

P2860

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

http://www.wikidata.org/entity/Q24530617

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@ast

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en-gb

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@nl

type

label

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@ast

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en-gb

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@nl

prefLabel

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@ast

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en-gb

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@nl

P1433

Q24530617-DA08E1AD-5A72-4CC0-90EA-50A133CCA851

P1476

Q24530617-9684D8DD-8DD1-4B0D-AEB4-2D1F99D20911

P2093

Q24530617-003C1EEB-80E5-4D55-A33D-D73AF7212B9C

Q24530617-0EF42938-E5EE-4465-91C6-C49C1A59DC17

Q24530617-372247DA-0CC9-4C82-8A92-00A44C369D4D

Q24530617-50992B10-9071-4FA0-8A62-F908560F87AE

Q24530617-58DBD2AD-2EDA-40A3-8740-1534C27E0C1E

Q24530617-63B8B965-C258-47D9-A009-9E6A4429B884

Q24530617-6A01C5E8-9CF1-44EC-BA24-AF1C2CE53FE3

Q24530617-6B1B6E28-D2A9-4BCD-B662-41BEC8655E12

Q24530617-73E32DE4-C3B0-46C2-9DE9-74632EEBAF02

Q24530617-7D95FC90-292D-47AF-A773-A499B12E6B18

P2860

Q24530617-0EBAD4D9-2B83-42EC-A78B-9045F665C103

Q24530617-128082D6-CA0D-4B34-B57F-1AACFE0A2CB7

Q24530617-1468DC3C-795F-4F4B-9567-FBBE066A7C5B

Q24530617-1CFCD159-EA24-4941-989D-8B2F7969EF4B

Q24530617-1D8FA100-8B06-4C7F-BAD0-04759FEF7275

Q24530617-26539867-D561-4C92-8BEA-7350454978C9

Q24530617-3622814E-2B81-4076-815C-5C8B1D9FD05E

Q24530617-37BA7924-323A-4D5D-BF76-328827E8F37F

Q24530617-37C3F80F-D043-452F-A50C-1CC61107F38C

Q24530617-3AA235BC-C37D-4AF1-83E6-DA17D3563B5E

P304

Q24530617-C106A095-843D-4713-85DA-2CA1F4CC9DF0

P31

Q24530617-04B3BCED-F749-4BC9-AF71-28225167EE96

P3181

Q24530617-91EBF932-0528-40A2-B8A6-14E16F8652A1

P356

Q24530617-DEA0A261-95F5-4AA8-9DF8-D580ED117B66

P407

Q24530617-FB78DCAD-A143-4B8D-A478-58805BC1A3BD

P433

Q24530617-7B7C9725-9188-40A2-989D-BA1BB7889D1C

P478

Q24530617-F467FCC1-DD45-4036-84D4-845AF1A82EFC

P50

Q24530617-4928FD96-A695-4DA3-87FD-79780FFB2366

Q24530617-9348153B-C617-4479-8374-D05520937A3D

P577

Q24530617-F69534D9-E315-4404-9E59-CBB707FE6BB8

P5875

Q24530617-B914E165-B66F-4A71-B00A-F37588A341A4

P698

Q24530617-DCC9380C-53B7-46E1-BB18-FB13EC6BDFD1

P921

Q24530617-EA5CD915-2A80-46B6-8DEB-5B38ABF35347

P932

Q24530617-74277992-8F90-47CB-9954-BBD134DCCDC9

P3181

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

@en

P2093

Alan R Collins

http://www.w3.org/2001/XMLSchema#string

Bryan A Laffitte

http://www.w3.org/2001/XMLSchema#string

Elaine McKilligin

http://www.w3.org/2001/XMLSchema#string

Grace Noh

http://www.w3.org/2001/XMLSchema#string

Graham N Hagger

http://www.w3.org/2001/XMLSchema#string

Joanne Goodman

http://www.w3.org/2001/XMLSchema#string

Jon L Collins

http://www.w3.org/2001/XMLSchema#string

Jonathan Tran

http://www.w3.org/2001/XMLSchema#string

Liming Pei

http://www.w3.org/2001/XMLSchema#string

Michael A Watson

http://www.w3.org/2001/XMLSchema#string

P2860

Role of LXRs in control of lipogenesis

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway

LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes

Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter

Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta

Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha

Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols

P304

7604-7609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2467007

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.112059299

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Aldons Jake Lusis

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11340838

http://www.w3.org/2001/XMLSchema#string

P698

12032330

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

124297

http://www.w3.org/2001/XMLSchema#string